A slot ma spaceman aposta onlinechine can have as many stops as its programmer desires. One reel could contain as many as twenty-two symbols. This has altered the way slot machine odds are calculated, and the 22 symbols on a single reel do not reflect the odds of winning combinations. The Random Number Continue reading “The Odds of Winning a Jackpot on a Slot Machine”
Radiation-Induced Myelosuppression Treatment Market Expected to Reach USD 3.5 Billion by 2028 at a 3.1% of CAGR
The Radiation-Induced Myelosuppression Treatment Market is poised for continued expansion, fueled by the growing burden of cancer and the widespread adoption of radiation therapy. According to a recent analysis by Future Market Insights (FMI), a leading market research firm, the market is currently valued at USD 2.9 billion in 2022. Over the next six years, it is projected to experience a steady Compound Annual Growth Rate (CAGR) of 3.1%, reaching a market valuation exceeding USD 3.5 billion by 2028.
This remarkable expansion is driven by several factors, notably the rapid improvement in healthcare infrastructure and the evolving reimbursement scenario. These factors have become pivotal boosters for the healthcare industry, particularly in developing regional markets.
Radiation therapy has been a significant part of cancer treatment and the consistently high success rate associated with radiotherapy is projected to further push demand for radiation-induced myelosuppression treatment worldwide.
Neutropenia is foreseen to generate maximum demand for radiation-induced myelosuppression treatment, whereas injectables are identified to hold a substantial share in the total market value, based on the route of administration of radiation-induced myelosuppression treatment. Thrombocytopenia and anemia are likely to present lucrative opportunities for radiation-induced myelosuppression treatment providers.
The report tracks key factors driving revenue growth of the market –
- Increasing prevalence of cancers
- Early diagnosis, promises improved chances of positive outcomes
- Fostering R&D funds supporting cancer research
- Strong product pipeline
- Bolstering adoption of chemo-radiotherapy in cancer treatment
Against the backdrop of patent expiry, a majority of market leaders are shifting their focus to the expansion of the product pipeline of a wide range of innovative formulations, likely to shape the radiation-induced myelosuppression treatment landscape.
- Myelo001 by Myelo Therapeutics GmbH recently received FDA approval as an orphan drug to be used in the ARS (acute radiation syndrome) treatment.
- Mylan NV and Pfizer Inc. also received FDA approvals for their recently launched biosimilars – Epogen Neupogen, and Neulasta respectively.
Patent expiry of originator biologics formulations is creating investment opportunities in biosimilar production – for the operators in the radiation-induced myelosuppression treatment landscape. As there is a considerable cost difference of around 20% between originator biologics and biosimilars, patients are inclined more towards an economical means of treatment, thereby fueling the scope of penetration of radiation-induced myelosuppression treatment in coming years.
Backed by a majority of established players housing strong bases across North America, especially the US, the report indicates a steady growth outlook for the Global Radiation-Induced Myelosuppression Treatment Industry in the region. North America will reportedly continue to account for over 65% share of the global market value.
New product launches currently mark the top developmental strategy adopted by leading companies competing in the Global Radiation-Induced Myelosuppression Treatment Industry. A majority of key players are also identified to focus on enhancing their geographical foothold in the global radiation-induced myelosuppression treatment landscape. The report in a distinct section covers some of the key competitors operating in the radiation-induced myelosuppression treatment marketplace, emphasizing their financial as well as strategic profiles in depth.
A few of the profiled companies include Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC (Johnson & Johnson), Amgen Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Novartis AG, and Partner Therapeutics, Inc.
In the highly consolidated competitive landscape of global radiation-induced myelosuppression treatment, the three top-ranking companies, i.e. Janssen Pharmaceutical NV, Amgen Inc., and Teva Pharmaceutical Industries Ltd. dominate in terms of market value. These players continue to hold winning revenue shares in the radiation-induced myelosuppression treatment owing to a strong global presence and a considerable number of new drug approvals. Established companies are entering strategic partnerships and collaborations with regional leaders, to achieve better penetration into regional markets.
Radiation-Induced Myelosuppression Treatment Market by Category
Indication:
- Neutropenia
- Anemia
- Thrombocytopenia
Drug Class:
- Growth factors
- Erythropoietin stimulating agents
- Thrombopoietin agents
- Iron supplements
Route of Administration:
- Oral
- Injectable
Distribution Channel:
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Drug stores
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
Advanced Wound Management Market Expected to Reach USD 11.5 Billion by 2033 at a 3.6% of CAGR
The Advanced Wound Management Market is on track for sustained growth, fueled by the rising demand for effective solutions to treat chronic and complex wounds. According to a recent market analysis, the market is anticipated to reach a value of USD 8.1 billion by the end of 2023. This positive trend is expected to continue, with the market projected to reach a significant USD 11.5 billion by 2033, reflecting a consistent Compound Annual Growth Rate (CAGR) of 3.6%.
The year 2020 presented unforeseen challenges for the advanced wound management sector, marked by the unprecedented impacts of the COVID-19 pandemic that induced a temporary decline in sales. However, the industry showcased its resilience as the global community rallied with intensified research and development efforts, focusing on innovative wound care solutions. This concerted effort has paved the way for a remarkable recovery, positioning the industry for a gradual and sustained upswing in the demand for advanced wound management products throughout the assessment period.
An exciting development to watch is the integration of biomaterials like alginates and silver into topical wound healing treatments, which is poised to further propel sales. These advancements are inspiring leading industry players to pioneer effective and cutting-edge solutions for advanced wound healing, ensuring a promising future for the market.
Product developments in the advanced wound dressing segment such as hydrogels, collagen, and hydrocolloids are on the cards. Apart from these products, the emergence of negative pressure wound therapy devices will boost sales in the market.
Besides this, government-backed initiatives such as public health insurance schemes in countries including the U.S., the U.K., and China will create lucrative growth opportunities in the advanced wound management industry.
Key Takeaways from the Advanced Wound Management Market Analysis
- Advanced wound dressing is anticipated to dominate the product segment.
- Based on application, chronic ulcers will witness increasing adoption of advanced wound management.
- Hospitals, followed by clinics are expected to account for maximum market sales.
- The U.S. is projected to witness high demand in the advanced wound management market, owing to the increasing number of diabetic patients in the country.
- The U.K. will emerge as a lucrative market with rapid product developments by leading players.
- China will exhibit a high demand for advanced wound management due to the increasing incidence of chronic wounds and reimbursements for medical expenditure.
- The advanced wound management industry in India is expected to grow at a steady pace, owing to growing cases of road accidents and chronic wounds.
“Increasing research and development activities aimed at offering advanced wound healing devices and fast-track approvals for novel advanced wound management products are anticipated to propel sales in the market through 2031,” says the FMI analyst.
Growing investments in the healthcare sector, coupled with innovations in advanced wound management products are anticipated to positively shape demand in the upcoming years.
Advanced Wound Management Market Competitive Landscape
As per FMI’s analysis, ConvaTec Group Plc. Coloplast A/S, Molnlycke Health Care AB, 3M Healthcare, and Smith & Nephew PLC are among the leading players in the market, accounting for approximately 3/4th of the market share.
Key players operating in the advanced wound management market are actively focusing on product innovations, strategic collaboration, mergers, acquisitions, and government approvals as a part of their growth strategies. For instance:
- In July 2021, Ethicon Inc., a part of the Johnson & Johnson Medical Devices Company, announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Designation for the company’s transbronchial microwave ablation technology. The advanced technology uses robotic-assisted bronchoscopy for the treatment of debilitating diseases and conditions.
- In July 2021, Illinois-based Medline Industries announced its plan to open a new distribution center worth US$ 100 Mn in the Katy area. The new distribution facility will bring the company’s total employee strength to around 375 employees.
Advanced Wound Management Market by Category
By Product Type:
- Advanced wound dressings
- Alginates
- Collagens
- Films
- Foams
- Hydrocolloids
- Hydrofibers
- Hydrogels
- Wound contact layers
- Superabsorbent dressings
- Negative pressure wound therapy devices
- Standalone NPWT devices
- Portable NPWT devices
- Single-use disposable NPWT devices
- NPWT accessories
By Application Type:
- Chronic ulcers
- Venous leg ulcers
- Diabetic foot ulcers
- Pressure ulcers
- Non-healing surgical wounds
- Traumatic wounds
- Burn cases
By End-User Type:
- Hospitals
- Clinics
- Ambulatory surgical centers
- Skilled nursing facilities
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
Dental Hygiene Devices Market Set to Reach USD 5.9 Billion by 2028 at a 4.8% of CAGR
The Dental Hygiene Devices Market is beaming with promise, driven by a growing focus on maintaining good oral health. A recent market analysis reveals a current market valuation of approximately USD 4.4 billion in 2022. Projecting forward, the market is anticipated to experience a steady growth trajectory, with a Compound Annual Growth Rate (CAGR) of 4.8% propelling it towards a staggering USD 5.9 billion by 2028.
Despite facing challenges, the Global Dental Hygiene Devices Industry has proven resilient, and the forecasted growth serves as a beacon of hope for industry stakeholders. The study offers a thorough analysis of the market’s historical trends and presents insights into its future trajectory, providing a valuable resource for informed decision-making.
Regional Insights: Regional markets play a pivotal role in the growth trajectory of the dental hygiene devices industry. Market dynamics, consumer preferences, and regulatory frameworks vary across regions, influencing the demand for dental hygiene devices. Understanding these regional nuances is crucial for businesses seeking to capitalize on emerging opportunities.
Recent Developments: The dental hygiene devices industry is witnessing rapid advancements, including the introduction of innovative dental technologies and products. From advanced toothbrushes and dental floss to cutting-edge dental imaging systems, recent developments are revolutionizing oral care practices and driving market growth.
Competitive Landscape: The competitive landscape of the dental hygiene devices market is marked by intense competition and a focus on product differentiation and market expansion.
As the Global Dental Hygiene Devices Industry embarks on a trajectory of unprecedented growth, stakeholders across the healthcare and dental sectors are poised to capitalize on emerging opportunities and drive innovation in oral care solutions.
Key Market Segments Covered in Dental Hygiene Devices Market Research
By Product:
- Tooth Brush
- Dental Polishing Devices
- Dental Scalers
- Other Dental devices
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia-Pacific
- Middle East and Africa (MEA)
Dental Hygiene Devices Market Players
- Colgate-Palmolive Company
- The Procter & Gamble Company
- Koninklijke Philips N.V.
- Unilever plc.
- GlaxoSmithKline plc
- Ultradent Products Inc.
- Johnson & Johnson
- 3M Company
- Dabur India Ltd.
- Dentsply Sirona.
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
Global Bronchoscopes Market Expected to Reach USD 647.7 Million by 2028 at a 4.4% of CAGR
According to Future Market Insights (FMI), the global Bronchoscopes Market size was valued at around USD 480.3 Million in 2021 and will grow 1.3X during the forecast period. During the projected period of 2022 to 2028, the market is expected to grow at a CAGR of 4.4%, with sales of USD 647.7 Million in 2028.
By the end of 2021, the global bronchoscopes market is predicted to account for about 4% of the global endoscopes market, which is expected to be valued at US $ 13.0 Billion in the same year. The rising prevalence of idiopathic pulmonary fibrosis, pulmonary fibrosis, interstitial pneumonitis, occupational sarcoidosis, and pulmonary haemorrhage is driving the global need for bronchoscopes and may create numerous prospects for manufacturers.
Cleaning conventional (multiple use) flexible bronchoscopes takes time and money, and there is a risk of cross infection. Cross-contamination is avoided by using a single-use flexible video bronchoscope. Early evaluation of the cost effectiveness of single-use bronchoscopes reveals possible hospital savings and patient advantages from prevented infections. Because of the appealing benefits, the increased use of single-use flexible bronchoscopes is creating a substantial market.
“Apart from the factors mentioned, technological advancements in the bronchoscopes landscape—witnessing a transformation shift from conventional invasive procedures to minimally invasive and advanced devices—is a critical factor determining the global demand for bronchoscopes, further amplifying its potential applications.
White-light bronchoscopy, Navigational bronchoscopy, and Autofluorescence (blue-light) bronchoscopy among others are some notable advancements and development, driving the global demand for bronchoscopes. Moreover, thin bronchoscopes with minimally invasive features are also gaining prominence. Manufacturers of bronchoscopes have built upon original bronchoscopes by making advancements, in terms of applicability and product versatility”, explains a senior analyst of the company.
Top Four Manufacturers Contribute the Largest Global Revenue
Considering the growing rate of technological advancements key manufacturers of broncoscopes, are making significant investments in the research and development initiatives to further increase the product efficiency. The global broncoscopes market showcases a highly competitive landscape characterized by relatively high barriers to entry, differentiated and well established products, and notable high profit margins.
Tier-1 manufacturers of bronchoscopes, including Olympus Corporation, FUJIFILM Holdings Corporation, Teleflex Incorporated, and HOYA Corporation, collectively hold a market share of approximately 62.5 percent—with Olympus Corporation contributing the largest revenue slice.
Tier-2 players such as KARL STORZ GmbH & Co KG, Ambu A/S, and Richard Wolf GmbH and tier-3 players including Rochling Group and Shanghai AoHua Photoelectricity Endoscope Co., Ltd, collectively contribute approximately 37.5 percent revenue share to the global bronchoscopes market. Key forward market strategies include:
- With continued improvements in the global healthcare setting, key players seek acquisition opportunities as a key growth strategy. Olympus Corporation, Fujifilm Holdings Corporation, Teleflex Incorporated, and HOYA Corporation are likely to focus on mergers, acquisitions, and collaborations strategies, in the coming years. HOYA Corporation, for instance, acquired C2 Therapeutics, to expand its interventional endoscopy offerings in the U.S. and also provide aftersales and repair services.
- Besides strategic tie-ups, new product launches will continue to be the key differentiation strategy, helping manufacturers to further solidify their market position. For instance, Olympus Corporation launched Truresolution objectives for multiphoton laser scanning microscopes. Teleflex Incorporated launched LMA® Gastro Airway, facilitating airway control during endoscopic procedures.
- Leading manufacturers of bronchoscopes are also focusing on geographical expansions, specifically in emerging nations, by acquiring local players in the endoscopy market.
Critical Market Restrainers Identified
- Risks of cross-contamination and post bronchoscopy infection in the form of bleeding, troubled breathing, and low blood oxygen level. FMI study indicates high infection rate at ambulatory surgical centers (ASCs), compared to clinics and hospitals.
- Growing demand for non-invasive procedures including liquid biopsy and Magnetic Resonance Spectroscopy.
- Stringency in regulations demanding a pre-market approval (PMA).
Bronchoscopes Market, By Category Product:
- Non-Video Bronchoscopes
- Video Bronchoscopes
Modality:
- Rigid Bronchoscopes
- Flexible Fiber Bronchoscopes
- Mobile Bronchoscopes
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
Growing Burden of Neurological Diseases Highlights Need for Innovative Treatments Like Vagus Nerve Stimulator Therapy
The rising prevalence of Vagus Nerve Stimulator Market in emerging countries has become a pressing health concern. According to estimates by the World Health Organization (WHO), between 4.5% and 11% of illnesses in both low- and high-income economies are attributed to neurological disorders. This alarming trend indicates a greater burden compared to patients suffering from respiratory ailments, gastrointestinal disorders, or cancers.
As the burden of neurological diseases is expected to increase further in the coming years, the consequences of neurological failure can be devastating, potentially leading to permanent paralysis or disability. Such conditions not only affect the patients but also impose significant challenges on their families and caregivers.
To address these complex health issues, Vagus Nerve Stimulator (VNS) therapy has been utilized for decades to alleviate symptoms associated with various neurological conditions, including tremors and dyskinesia. This innovative therapy works by creating muscle contractions that can help restore functionality to motor nerves.
In addition to improving motor functions, VNS therapy has shown promise in treating a variety of other neurological disorders, including migraines, Crohn’s disease, asthma, depression, headaches, and even certain cardiovascular diseases. As healthcare professionals continue to explore the potential of VNS therapy, its role in normalizing neurological functions and improving patient quality of life is increasingly recognized.
The growing need for effective treatments for neurological disorders underscores the importance of ongoing research and innovation in this field, paving the way for improved patient outcomes and a better quality of life.
For further information and insights on neurological treatments and innovations, please refer to upcoming publications and reports.
Driven by a paradigm shift from implantables to non/minimally invasive devices, the vagus nerve stimulator (VNS) landscape is gradually encouraging the growth of transcutaneous VNS to be witnessed over the next couple of decades. Moreover, growing R&D efforts in the integration of next-generation technology to bypass the shortcomings of implantable VNS is likely to shape the future of vagus nerve stimulator marketplace.
- Of the total global population inflicted by neurological disorders, approximately 50% suffers from an epileptic disorder, research and surveys say.
- Vagus nerve stimulation is witnessing a rapidly expanding applicability beyond epilepsy, in the recent past.
- Research uncovers potential efficiency of vagus nerve stimulation in the obesity management of depression patients.
- Positive outcome of vagus nerve stimulation in treatment-resistant depression and epilepsy surgery indicate promising opportunities approaching in the near future.
Europe Steals the Limelight, Crossing US$ 100 Million Revenue in 2019
North America currently holds a massive revenue share in the vagus nerve stimulator market, and FMi projects continued dominance of this region over other regional markets in comping years. However, the report forecasts emergence of Europe and Asia Pacific (excluding Japan) as highly attractive territories for key market players in the near future. Europe will reportedly cross the US$ 100 million mark in 2019, reflecting the most lucrative opportunities for vagus nerve stimulator manufacturers.
“At present, Europe and APEJ hold a collective revenue share of over 40% in market, of which the former is gradually moving towards extending its individual market value share up to 1/4th of the global revenue,” explains a senior research analyst at FMI. Adding further, the analyst says, “Favorable regulatory and reimbursement scenario across Europe and relatively easy availability of VNS systems are most prominently driving the growth of vagus nerve stimulator market in Europe. VNS sales in Europe will also benefit from the strong presence of leading industry manufacturers in the region”.
Taxonomical Insights – By Type, Application, and End User
- By the type of vagus nerve stimulator, implantable stimulator continues to bring in the most of the revenue to market.
- Epileptic seizures secure the spot of the most sought after application type in vagus nerve stimulator landscape.
- Hospitals remain the largest end user of vagus nerve stimulator. FMI research indicates that specialty clinics and home care settings are emerging as attractive end user candidates in recent years.
Thorough competition analysis of vagus nerve stimulator landscape reveals a few important developmental strategies that are ruling the minds of VNS manufacturers at present.
- Besides geographical expansion, leading players in vagus nerve stimulator market are focusing on the extension of their existing offerings portfolio, according to the report.
- In an effort to address the challenges to VNS adoption posed by the high price point, companies are now reassessing their pricing strategies for a competitive advantage.
- A number of companies are also directing their strategic focus on a stronger distribution network.
- Strategic partnerships with local and regional distributors and retailers hold immense importance for the competitors in VNS landscape.
- Long-term contractual collaborations with recognized hospitals, research and pathology laboratories, and CROs are emerging as a growing trend among manufacturers of vagus nerve stimulator.
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
Recombinant Vaccines Market Set for Growth Amid Strategic Investments and Government Initiatives
Mature regional markets in North America and Europe remain differentiated due to effective presence of leading biopharmaceutical companies that boast of GMP certified sterile manufacturing facilities, contributing significant towards the revenue growth of Recombinant Vaccines Market in these regions.
Relatively safer and affordable, recombinant vaccines are gaining ground worldwide. With growing focus on preventive healthcare, vaccines are gathering momentum at a global level, including developing economies that still continue to struggle with severe demand-supply gap leading to a considerable shortfall in the availability of vaccines. However, a number of leading non-profit organizations are constantly initiating funding collaborations for improved accessibility of critical vaccines across developing countries.
A new Future Market Insights study on the global recombinant vaccines landscape highlights the optimistic revenue growth potential in developing regional markets such as Asia Pacific and Japan. The FMI report also offers an extensive analysis of the current competition scenario — emphasizing exclusive insights drawn by exhaustive primary and secondary market research.
Key Dynamics Analysis Evaluates the Role of Collaborative Activities and R&D
On the backdrop of how Sanofi’s acquisition of protein Sciences in 2017 has been boosting the former’s Flubok (recombinant vaccines for flu) manufacturing capacity, several players in recombinant vaccines space are strategizing mutual alliances in coming years. Strategic collaborations between leading players in the recombinant vaccines space is likely to provide a strong impetus to the overall market growth.
Moreover, according to WHO, growing prevalence of rare disease instances such as Ebola, Crimean Congo, MERS, hemorrhagic fever, Marburg, Lassa Fever, Nipah, SARS coronavirus diseases, and Rift Valley Fever is attracting R&D interests of recombinant vaccines manufacturers, thereby pushing growth of the market in the near future
FMI Study Positions Western Europe as Growth Engine of Recombinant Vaccines Landscape
Western Europe currently represents just-under 1/3rd share of the global market revenue, attributed to growing government support for vaccine development and vaccination campaigns. Strong presence of key market players in this region and their increasing investments in R&D of recombinant vaccines further accentuate Western Europe’s top performing spot.
The report projects impressive growth prospects for Asia Pacific and Japan in coming years. However, APAC is especially portrayed lucrative owing to dramatically growing healthcare spending and an expanding target population that struggles with highly unmet clinical needs, despite growing consumer awareness about vaccination merits.
Segmental Analysis Reveals Neck-on-Neck Competition between Subunit and Attenuated Vaccine Types
- Based on the recombinant vaccines market assessment by type, subunit recombinant vaccines currently hold the largest value share but are likely to lose a bit of it to attenuated recombinant vaccines. Both the segments collectively cover around 90% share of the total market revenue.
- Applications of recombinant vaccines in human vaccination continue to reflect maximum attractiveness over veterinary applications. A majority of the total market revenue is contributed by recombinant vaccines for humans, as indicated by the report.
- Private clinics and dispensaries remain the most preferred channel for vaccines distribution, followed by pharmacies. Hospital pharmacies hold a larger share than retail pharmacies, though latter is poised for promising expansion in coming years.
Top Two Players Represent a Whopping 80% Market Value Share, Concludes Competition Analysis
According to the FMI study, GlaxoSmithKline plc and Merck & Co., Inc. collectively account for more than 80% revenue share in recombinant vaccines marketplace, keeping the landscape highly consolidated. While the former primarily focuses on strategic collaborations, the latter strategizes new product launches for an expanded market share.
- GSK’s candidate vaccine launched in 2017 claims to prevent pulmonary TB in HIV negative adult patients.
- Merck announced the three studies of the first phase of its investigational pneumococcal vaccine, early in 2018.
Competition tracking uncovers a few more important insights that can potentially direct strategy building efforts of competitors in the recombinant vaccines market at a global level.
- New market entry aspirants are prominently opting for the adoption of mammalian protein expression systems in recombinant vaccines manufacturing that accelerate the entire production process.
- Established players in recombinant vaccines landscape are prioritizing the development of new variants of existing vaccines.
- Contractual alliances with non-profit organizations are likely to earn higher profit shares for manufacturing leaders in recombinant vaccines market.
Segmentation
The report on the recombinant vaccines market provides salient information on market players. The recombinant vaccines market is segmented by region, product type, application, and distribution channel, to analyze segment-wise growth of the recombinant vaccines market. Based on regions, the recombinant vaccines market is segmented into seven regions – North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, and the Middle East & Africa (MEA).
The recombinant vaccines market by product type is segmented intosubunit recombinant vaccines, attenuated recombinant vaccines, vector recombinant vaccines. By application, the recombinant vaccines market is segregated into human, and veterinary recombinant vaccines. By distribution channel, the recombinant vaccines market is segregated into hospitals, private clinics & dispensaries, retail pharmacies & others.
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
Appendage Management Market Projected to Reach USD 352.5 Million by 2028 at a 6.6% of CAGR
The global appendage management market is estimated to grow from USD 223.9 million in 2021 to USD 352.5 million by the end of 2028, reflecting a CAGR of 6.6% during the forecast period.
This growth is fueled by the increasing demand for advanced medical solutions and technologies to manage appendage conditions, which are often linked to various health issues. As healthcare providers focus on improving patient outcomes and enhancing the quality of care, the appendage management market is set to experience significant expansion.
Key Market Drivers
The rising incidence of appendage-related disorders, combined with advancements in surgical techniques and treatment options, is driving market growth. Additionally, the growing awareness of preventive healthcare and the need for effective management of appendage conditions are contributing to the market’s upward trajectory.
For further insights into market trends and projections, Future Market Insights provides a comprehensive report on the appendage management market.
Key Insights on Competitive Landscape Analysis of Global Appendage Management Market
As per the FMI analysis, given the high revenue contribution by the top five players—including Boston Scientific Corporation, AtriCure, Inc., Abbott Laboratories, Cardia, Inc., and Medtronic plc—holding an accumulative revenue share of nearly 89 percent, the global appendage management market showcases a highly consolidated landscape. FMI’s research also indicates that smaller players contribute approximately 11.5 percent of revenue share to the global appendage management market. A much more careful competitive landscape analysis of the global appendage management market reveals a 3-tier segmentation—depending upon the growth stage of various companies.
- With reach wide enough in North America, Boston Scientific Corporation and AtriCure, Inc. are the clear market leaders—for endocardial and epicardial left atrial closure devices, respectively. With an accumulative share of approximately 57 percent in the appendage management market, Boston Scientific Corporation’s WATCHMAN and AtriCure, Inc.’s products are in direct competition. However, WATCHMAN is most widely implanted and trusted—boasting FDA approval and CE Mark
- Mid-stage growth companies including Abbott Laboratories and Cardia, Inc have pulled away from the top two players, in the last few years—holding approximately 32 percent market share. These companies, however, have an expansive range of product offerings. Holding nearly 14 percent in terms of revenue, Abbott Laboratories is upping its portfolio of upper and lower extremities along with popularization of the product with good clinical trial results.
- The emerging players, including SentreHEART, Inc., LifeTech Scientific Co., Ltd, Occlutech International AB, and Johnson & Johnson Services, Inc. are more focused on product innovation and differentiation within certain treatment niches, to build a strong market position in the consolidated appendage management landscape. In spite of a miniscule market share, FMI foresees notable potential of their research and development initiatives in the long run.
In terms of overall forward market strategies, key companies are projected to focus on innovating easily implantable, life-saving products for patients suffering from atrial fibrillation, thereby, eliminating the side-effects caused by drugs taken to treat atrial fibrillation. Innovative devices and better navigation and visualization technologies are expected to bring significant opportunities—translating into increased adoption of Left Atrial Appendage (LAA) closure devices by catheterization laboratories and hospitals.
Moreover, mergers and acquisitions will remain a key expansion strategy among players in appendage management market. FMI indicates that acquisitions in the global appendage management market would prove beneficial for the key leaders considering the increasing number of promising on-going or successful researches by emerging companies. Already in a dominant position, key players are increasingly focusing in strengthening the supply chain and distribution networks through strategic partnerships to maximize their market share.
Bonus: Key Market Influencers
- Notable success rate of appendage management procedures.
- Non-surgical, minimal invasion approach helping in fast recovery and reduced surgical and implantation complications.
- Drawback of oral anticoagulant drugs to push the demand for appendage management procedures.
Appendage management market by Category By Product Type
- Epicardial LAA Closure Devices
- Endocardial LAA Closure Device
By End User
- Hospitals
- Cath Labs
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
Endoscopy Fluid Management Systems Market Set to Reach USD 683 Million by 2028 at a 7.4% of CAGR
The global endoscopy fluid management systems market was valued at USD 414 million in 2021 and is projected to experience robust growth, reaching an estimated USD 683 million by 2028. The market is anticipated to expand at a CAGR of 7.4% during the forecast period.
This growth can be attributed to the increasing adoption of endoscopic procedures and the rising demand for advanced medical technologies that enhance surgical outcomes. Endoscopy fluid management systems play a critical role in maintaining optimal fluid levels during procedures, which is essential for ensuring patient safety and improving procedural efficiency.
Key Market Drivers
The rising prevalence of chronic diseases, coupled with an aging population, is driving the demand for minimally invasive surgical techniques, further boosting the need for effective fluid management solutions. Innovations in endoscopy technologies and the growing emphasis on improving patient care are also contributing to the market’s expansion.
For a detailed analysis of market trends and future projections, Future Market Insights offers comprehensive insights into the endoscopy fluid management systems market.
Prominent Players:
Karl Storz GmbH & Co KG
Olympus Corporation
Richard Wolf GmbH
Smith & Nephew
Stryker Corporation
DePuy Synthes (Johnson & Johnson Services Inc.)
Cantel Medical Corporation
Medtronics Plc.
B. Braun Medical Inc. and Hologic Inc
Healthy Year over Year Revenue Growth Projected for Asia Pacific
APAC has become the hotspot for leading medical device companies, which is further intensified by dramatically growing medical tourism sector. Across APAC, Japan is likely to account for substantial revenue generation, enabling the regional market secure second spot in the global endoscopy fluid management systems landscape. FMI projects over 7% year on year revenue growth in 2020 and beyond, for this regional market.
Government Regulations Favor Market Growth in Latin America
Latin American market for endoscopy fluid management systems is thriving at a promising pace owing to favorable government initiatives regarding endoscopic procedures and medical device marketing. Noteworthy demand for laparoscopy suction irrigation pumps within the region is identified to be responsible for the rapid revenue growth of endoscopy fluid management systems marketplace across Latin America.
Key Segments Covered in Endoscopy Fluid Management Systems Industry Survey:
Endoscopy Fluid Management Systems Market by Product Type:
- Laparoscopy endoscopy fluid management systems
- Hysteroscopy endoscopy fluid management systems
Endoscopy Fluid Management Systems Market by Modality:
- Floor Standing endoscopy fluid management systems
- Benchtop fluid management systems
Endoscopy Fluid Management Systems Market by End-User:
- Hospitals endoscopy fluid management systems
- Ambulatory surgical centers endoscopy fluid management systems
- Specialty clinics endoscopy fluid management systems
- Diagnostic centers endoscopy fluid management systems
Endoscopy Fluid Management Systems Market by Region:
- North America endoscopy fluid management systems Market
- Latin America endoscopy fluid management systems Market
- Europe endoscopy fluid management systems Market
- East Asia endoscopy fluid management systems Market
- South Asia & Pacific endoscopy fluid management systems Market
- Middle East & Africa (MEA) endoscopy fluid management systems Market
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
Narcolepsy Treatment Industry Poised for USD 6.67 Billion Valuation by 2028, Driven by a 5.7% CAGR
The Global Narcolepsy Treatment Industry From an expected USD 4.77 billion in 2022, the market for narcolepsy treatment is projected to grow at a CAGR of 5.7% to reach USD 6.67 billion by 2028. (2022-2028).
In its recently released market intelligence overview, Future Market Insights (FMI) underlines the significant need for narcolepsy treatment in North America. Given the growing inclination towards the use of prescription medicines and adherence to the same on a long-term basis, the narcolepsy treatment landscape in Europe will experience significant revenue growth.
The neurobiology of sleep has advanced significantly over the past few decades, mostly as a result of the proliferation of animal models for investigating the neurological functions of the brain and any potential complexities. This also takes into account the part the brain plays in sleep.
Asia Pacific among other emerging economies including MEA and Latin America, on the other hand, are expected to showcase positive trends towards the adoption of narcolepsy treatment, due to:
- Strong distribution pipeline of narcolepsy drugs.
- Emerging global and local biopharmaceutical companies.
- Increasing incidences of Obstructive Sleep Apnea (OSA) in Latin America. Obesity is reported to be the most common risk factor.
- The prevalence of moderately severe sleep apnea is estimated to be around 5% in women and 10% in men in South Africa. It is estimated that up to 90% of patients are undiagnosed.
- The prevalence of sleep apnea is more severe in developing countries due to the lack of skilled physicians
In terms of key forward market strategies, the primary objective of manufacturers in the Global Narcolepsy Treatment Industry is to expand their footprint in the various regional markets, to solidify their market position.
Key Findings from the Regional and Competitive Landscape Analysis of the Global Narcolepsy Treatment Industry
- Leading narcolepsy treatment manufacturers are prioritizing regional-specific product development. The product portfolio expansion is mostly targeted in Asia Pacific.
- Apart from new product development—mostly arising from the presence of low-cost generic versions of patented drugs, strategic partnerships and acquisitions with pave the way for further business expansions.
- Manufacturers in the global narcolepsy treatment are also focused on introducing new research and development units in different geographic regions.
- Industry leaders are focusing on maintaining long-term partnerships with pharmacies- in hospitals and retail, drug stores, and e-commerce. Sales through an e-commerce distribution channel are expected to contribute a significant revenue share in the Global Narcolepsy Treatment Industry.
- FMI has also noted an increasing focus on the reformulation of well-known products and combinations, by manufacturers in North America to achieve higher sales and wide penetration
There is a conscious shift from OTC medication to devices treating narcolepsy, driving significant revenue growth for the devices segment compared to drugs. Growing incidences of inappropriate medication and addiction, translating into severe side effects including headache, prolonged drowsiness, daytime memory and performance problems, allergic reactions, and death in some cases, is the key driving factor. These side effects are associated with OTC as well as prescription-based sleep aids.
Growing demand to treat narcolepsy with BiPAP is expected to push this segment of devices—predicted to expand at the highest CAGR. Moreover, devices in portable and available-for-rent formats will translate into higher adoption rates, throughout the forecast period. Portable Continuous positive airway pressure (CPAP) devices are lighter and smaller and can also be used as a home-based unit, further reducing the dependency on OTC pills and prescription drugs.
While explaining the growth trajectory of the Global Narcolepsy Treatment Industry, a senior analyst from the healthcare domain underscores growing healthcare expenditure and rising incidence cases of fracture fixation and orthopedic disorders as key factors contributing to the demand for narcolepsy treatment through 2028. “Regulatory impositions by various global authorities including the FDA and European Commission along with currency fluctuations, regulations, and changing taxation policies are some high-impact factors pushing the global demand for narcolepsy treatment”, the analyst further explains.
Critical Market Restrainers
Although the narcolepsy market is expanding at a robust CAGR, long waiting times for sleep services, lack of awareness and delayed diagnosis, severe side effects of sleep aid medication, lack of proper documentation for the usage and licensing of sleeping pills, and improper equipment regulations are some critical factors projected to restrain the growth of Global Narcolepsy Treatment Industry.
Key Market Segments Covered in Global Narcolepsy Treatment Industry Research
By Product:
- Narcolepsy Treatment Drugs
- Modafinil
- Sodium Oxybate
- Armodafinil
- Others
- Devices
- CPAP Devices
- BiPAP Devices
- APAP Devices
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- e-commerce
- Drug Stores
- Others
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube